Mezlocillin is a new broad-spectrum semisynthetic penicillin that has shown encouraging in vitro activity against the infecting organisms most likely to cause mortality and morbidity in cancer patients receiving chemotherapy. The serum clearances and urine recoveries of mezlocillin, ampicillin, and carbenicillin were compared after the intravenous administration of single 3-g doses. The peak mean serum concentrations of mezlocillin and carbenicillin were 269 and 278 ,ug/ml, respectively, whereas the peak ampicillin level was lower at 167 ,ug/ml. The terminal half-life of mezlocillin, 66 min, was not significantly different from those of ampicillin and carbencillin (63 and 77 min, respectively). Recoveries of mezlocillin, ampicillin, and carbenicillin from urine over 6-h periods after drug dosage were 45, 61, and 80%, respectively. A further study in 11 cancer patients examined serum maintenance levels of mezlocillin when 3-g doses were given intravenously every 4 h for at least 7 consecutive days. After 3 days of therapy, the mean serum concentrations were maintained above 50 ,ug/ml. Although therapeutic efficacy was not an objective of this study, all of three documented bacterial infections were cured, and no serious toxicity was encountered.
Mezlocillin, {2S-[2a, 5a, 6,8 (S)]} -3,3-dimethyl-6 {[( {3-(methylsulfonyl)-2-oxo-1-imidazolidinyl]carbonyl) -amino)phenylacetyl]amino}
-7-oxo-4-thia-1-azabicyclo(3,2,O)heptane-2-carboxylic acid, is a new semi-synthetic penicillin with a broad spectrum of antibacterial activity. In vitro testing showed mezlocillin to be more active than ampicillin, carbenicillin, and cephalothin against Escherichia coli, Enterobacter sp., Serratia sp., Pseudomonas aeruginosa, and indole-positive Proteus sp. It was as active as cephalothin and more active than ampicillin and carbenicillin against Klebsiella sp. and was active against Proteus mirabilis and gram-positive cocci, except penicillin G-resistant Staphylococcus aureus (5) .
Klebsiella pneumoniae, P. aeruginosa, and E. coli are the major infecting organisms causing mortality and morbidity in cancer patients (4) .
Carbenicillin, which is active against Pseudomonas sp., is less active against E. coli and has no activity against Klebsiella sp. The most effective therapy for these infections has been with penicillin derivatives or cephalosporins combined with an aminoglycoside, which has the potential for serious nephrotoxicity (3, 15) . Because of the need to develop more effective and less toxic antibiotics, serum clearance and urine recovery studies of mezlocillin were conducted.
MATERIALS AND METHODS
Pharmacology studies were conducted in 20 cancer patients with a medium age of 45 years (range 18 to 73 years). There were 14 males and 9 females. In all patients, urinalysis, concentrations of urea nitrogen in whole blood, and concentrations of bilirubin and glutamic-oxaloacetic transaminase in serum were within normal limits when measured within 7 days of starting the studies.
Nine patients received single doses of mezlocillin, carbenicillin, or ampicillin via random assignment with an interval of at least 2 days between serial drug studies. Three grams of the respective agents, dissolved in 50 ml of 5% dextrose solution, was administered intravenously in a 15-min period. Blood samples were collected before drug administration and 0.25, 0.5, 1, 1.5, 2, 3, 4, and 6 h thereafter. Urine samples were collected immediately before drug dosage and used for base line control assays. Thereafter, all voided urine was collected for 6 h, and during this time it was stored at the bedside on ice. At the end of 6 h, the total volume was recorded, and a 10-ml sample was taken for assay.
A serum maintenance study was conducted in 11 patients who had developed fever of 101°F (ca. 38°0) or greater and were suspected of having infection.
Patients received 3 g of mezlocillin administered intravenously in 100 ml of 5% dextrose solution over a 2-h period every 4 The differences between the serum concentrations of mezlocillin and the other penicillins at each sampled time were subjected to statistical analysis by Student's t test for each of the nine patients.
RESULTS
The serum concentrations at 0.25 h after rapid intravenous injection of 3-g doses of mezlocillin, carbenicillin, and ampicillin were 269, 278, and 147 ug/ml, respectively (Fig. 1) . Mean serum concentrations of these drugs were 10, 25, and 6 ug/ml at 4 h and 3, 7, and 2 pg/ml at 6 h. The terminal half-life of mezlocillin was 66 min and was not significantly different from that of ampicillin or carbenicillin (63 and 77 min, respectively) when statistically analyzed as previously described. For mezlocillin compared with ampicillin, the P values ranged from 0.1 to 0.06, and, for mezlocillin compared with carbenicillin, the P values ranged from 0.3 to 0.2. There were differences in the urinary excretion of the three penicillins during the 6-h observation, with recoveries ranging from 45% of the administered dose for mezlocillin to 61 and 80% for ampicillin and carbenicillin, respectively (Table 1 ). These differences in recovery were not due to differences of antibiotic stability. Each drug was added to fresh pooled human urine and allowed to stand under the same conditions as for the study; 88% of mezlocillin, 83% of ampicillin, and 83% of carbenicillin were recoverable after 6 h. Figure 2 shows the results of the serum maintenance study. The mean peak serum concentrations were achieved at 2 h and were over 100 pg/ml. Day 3 and day 7 studies showed mean serum levels maintained above 50 pg/ml at all sampled times. Also, the levels on these days were almost identical, revealing no evidence of drug accumulation.
Although the objective of this study was not to determine therapeutic efficacy, 3 of the 11 patients on the serum maintenance study had documented bacterial infections and were cured. These included one P. aeruginosa one K. pneumoniae urinary tract ir one S. aureus pneumonia and em remaining eight patients had fever origin, which resolved during the st dence of acute toxicity associated w lin dosage was observed. During the tenance study, one patient had a r cylic acid test for proteinuria doc day 4 and day 6 of antibiotic adr Unfortunately, other tests for prot not completed. However, this was n( with change in voided volume, abr microscopy, or deterioration of bloo gen and serum creatinine. Also no was found on retesting 72 h aftei was discontinued.
DISCUSSION
In the comparative single-dose ance study, the mean peak serum le cillin was higher than that of arn similar to that of carbenicillin. T half-life of mezlocillin, however, wa cantly different from that of ampi( benicillin. The half-lives of ampici benicillin in this study are of the se (5) . Also, this level should be effective over 2 h every against 70% of isolates of Bacteroides fragilis and most other anaerobic bacteria (17) .
The only mezlocillin-associated abnormality observed was positive sulfosalicylic acid testing septicemia, for proteinuria in one patient. This was fully ifection, and reversible and was not associated with any other ipyema. The recognized renal abnormality. The renal toxicity of unknown of penicillins resulting in interstitial nephritis ;udy. No evi-and occasionally in renal failure is well described ith mezlocil- (1, 6-8, 11, 16) . However, proteinuria without serum main-any other associated abnormalities of renal func-4+ sulfosali-tion is unusual. Observations of further patients umented on receiving mezlocillin at our institution suggest ministration. that this may represent a pseudoproteinuria, einuria were which has been reported with another penicillin, ot associated nafcillin (13) . Further careful and more extensive iormal urine observations of renal function are jcurrently id urea nitro-being undertaken in patients receiving this drug. abnormality Mezlocillin appears to be a penicillin with a r mezlocillin wide range of activity against the bacteria that are most likely to result in morbidity and mortality in the cancer patient population. Therapeutic blood levels are readily achieved, and no serum clear-serious toxicity has been encountered. 
